2026.02. 10 本文字数：855，阅读时长大约2分钟 作者 | 第一财经 钱童心 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿 美元，同比增长8%，其中阿斯利康中国2025年总营收达66.54亿美元，同比增长4%，占总收入比 约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季 度，阿斯利康肿瘤药业务增长20%至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5 亿美元。 阿斯利康CEO苏博科（Pascal Soriot）表示，2025年，阿斯利康宣布了16项积极的三期研究结 果，目前共有16种畅销药物。他还表示，公司今年预计还将公布超过20项三期试验结果，且还有 100多项三期临床试验正在进行中，包括多种创新技术疗法。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进 行投资来实现。公司计划到2030年推出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到 ...

阿斯利康今年预计还将公布超过20项三期试验结果，且还有100多项三期临床试验正在进行中，包括多种创新技术疗法。 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿美元，同比增长8%，其中阿斯利康中国 2025年总营收达66.54亿美元，同比增长4%，占总收入比约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季度，阿斯利康肿瘤药业务增长20% 至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5亿美元。 阿斯利康近期还调整了上市架构，普通股于2月2日在纽约证券交易所开始交易。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进行投资来实现。公司计划到2030年推 出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到2030年将在中国投资超1000亿元人民币，以扩大在药 品生产与研发领域的布局。这也是阿斯利康史上最大规模对华投资计划。 过去几年来，阿斯利康不断加大与中国领先生 ...

Economic Growth - Singapore's GDP growth for 2025 is projected at 4.8%, an increase of 0.4 percentage points from 4.4% in 2024, marking the strongest growth since 2021 [1] - The manufacturing sector is identified as the core engine of growth, with an annual output increase of 7.6% and a quarterly growth of 15% in Q4 [1] - The services sector is expected to grow by 4.1% in 2025, slightly lower than the 4.3% growth in 2024, with significant contributions from information and communication, finance, and professional services [2] Manufacturing Sector - The biopharmaceutical and electronics industries are highlighted as dual pillars of growth, benefiting from concentrated orders in tumor drugs and vaccines, as well as the AI development wave [1] - Integrated circuit exports are projected to increase by 32.1%, disk media products by 53.5%, and communication equipment by 81.4%, reflecting strong demand for high-end manufacturing driven by global AI infrastructure investments [1] Services Sector - The services sector shows a clear internal structural differentiation, with traditional consumer services like accommodation and food services growing only 3.2%, significantly lower than the previous year's 4.6% [2] - New emerging businesses such as digital trust and cross-border carbon credit management contributed over 300 million SGD to revenue, reinforcing Singapore's position as a leader in sustainable finance within ASEAN [2] Construction Sector - The construction industry is expected to grow by 4.2% in 2025, a significant decline from the 9.2% growth in 2024, yet still maintaining positive growth amid high interest rates and labor shortages [3] - The government has introduced a "Construction 4.0 Transformation Blueprint" to mandate the use of digital technologies in large projects, aiming to drive technological upgrades in the sector [3] Trade Performance - Non-oil domestic exports are projected to grow by 4.8%, aligning with GDP growth and significantly higher than the 0.2% growth in 2024 [4] - Electronic exports have maintained double-digit growth for four consecutive months, offsetting declines in other sectors such as petrochemicals and shipbuilding [4] Future Outlook - The Ministry of Trade and Industry forecasts a GDP growth range of 1% to 3% for 2026, reflecting a cautious approach amid external headwinds and internal transformation challenges [5] - The government plans to launch a new economic strategy review, focusing on enhancing supply chain resilience, deepening AI and advanced manufacturing integration, and expanding regional service trade networks [5]

Core Insights - The JPMorgan Healthcare Conference is taking place at a pivotal moment in the global innovative drug landscape, with major pharmaceutical companies increasingly focusing on innovative drugs developed in China as their blockbuster drug patents near expiration [1][3] Group 1: Conference Overview - The annual JPMorgan Healthcare Conference is the most anticipated investment summit in the pharmaceutical industry, attracting investors, bankers, pharmaceutical executives, and lawyers [1] - Hotel prices in San Francisco have surged, with many hotels near the conference venue fully booked, indicating high demand from attendees [1] Group 2: Market Trends - There is a growing expectation that acquisitions of innovative drugs will be more valued than mergers among large pharmaceutical companies, as competition for quality pharmaceutical assets intensifies [3] - The acquisition price for innovative drugs is expected to be significant, exemplified by the over $10 billion deal for the weight-loss drug innovation company Metsera, contested by Novo Nordisk and Pfizer [3] - A new wave of pharmaceutical industry acquisitions is anticipated by 2026, potentially surpassing the peak transaction volumes of nearly $500 billion seen in 2019 and 2021 [3] - According to LSEG data, global pharmaceutical mergers and acquisitions are projected to grow by 56% year-on-year in 2025, reaching $403 billion [3] Group 3: Acquisition Focus Areas - A survey by JPMorgan indicates that 60% of respondents expect a rebound in biopharmaceutical mergers and acquisitions by 2026, with oncology drugs, rare disease drugs, neurological drugs, and cardiovascular metabolic drugs, including weight-loss medications, identified as hot acquisition areas [4]

Group 1 - The "2025 Financial Annual Conference" held in Beijing focused on high-quality development of listed companies, emphasizing resilience and growth through cycles, with participation from over 200 listed companies and various industry leaders [1] - The "Golden Intelligence Award" was announced, recognizing over 140 companies, including Haier Smart Home and Dongpeng Beverage, for their exemplary high-quality development among more than 8,000 A-share, Hong Kong stock, and Chinese concept stocks [1] Group 2 - Evolution Medical's COO highlighted significant opportunities in China's innovative drug sector, particularly in oncology, with technology sourced from Peking University and expected to enter human trials by 2026 [3] - As of November 18, 2025, the total amount of domestic innovative drug licensing has surpassed $100 billion, doubling from 2024, marking China as a significant player in the global biopharmaceutical landscape [3] - The growth of China's innovative drug sector is supported by three key factors: continuous policy support, a solid industrial foundation with ample talent and patient base, and enhanced global market demand and competitiveness [3] Group 3 - Evolution Medical proposed strategies for startups to transition from following innovation to leading global innovation, leveraging China's cost and efficiency advantages [4] - The company emphasized the importance of a dual-circulation development model, with a strong domestic market supporting rapid commercialization and international collaborations with major pharmaceutical companies [4] - Four core relationships were identified for successful drug development: proactive positioning, low-cost rapid trial and error, long-term resource commitment, and improved operational efficiency [4] Group 4 - The insights provided by Evolution Medical's COO outline a clear path for China's biopharmaceutical industry to shift from a follower to a leader, driven by policy benefits, industry accumulation, and global demand [5]

Group 1 - The underlying logic of family asset allocation is being restructured, moving away from reliance on single assets towards diversified global asset allocation as a necessity for households [1] - The podcast discusses how families can seize opportunities presented by the global technological wave [1] Group 2 - The Hong Kong technology sector is gaining attention due to improvements in fundamentals and positive expectations, making it a valuable long-term investment [4] - Many companies listed in Hong Kong are familiar to mainland investors, providing a sense of comfort and understanding [4] Group 3 - High volatility in technology assets requires investors to be aware of potential pitfalls and to adopt strategies that align with their risk tolerance [5] - A systematic investment approach, such as dollar-cost averaging, may yield better results in volatile markets [5] Group 4 - The reversal of the "dilemma" in innovative pharmaceuticals is attributed to changes in the payment side and ongoing policy support for innovative drugs [6] - The upcoming expiration of patents for many multinational corporations (MNCs) creates opportunities for Chinese innovative pharmaceutical companies, which are seen as a "pharmaceutical supermarket" globally [7] Group 5 - The lithium battery sector is experiencing a second growth curve driven by explosive growth in energy storage demand, supported by technological advancements and new applications [9][10] - The commercialization of energy storage has been accelerated by high electricity demand in certain provinces and supportive government policies [10] Group 6 - India is emerging as a new focus for global capital due to its stable currency, young population, and low labor costs, positioning it as a strong candidate for becoming a major economy [11]

Core Viewpoint - The National Medical Products Administration (NMPA) has proposed a draft to optimize the clinical trial review and approval process for innovative drugs, potentially reducing the approval timeline to 30 working days for core innovative drug varieties, which may reshape China's innovative drug development landscape [1][3][4]. Summary by Sections Clinical Trial Review and Approval Optimization - The draft aims to significantly enhance the efficiency of drug development, marking a key step towards establishing China as a global hub for innovative drug research [3][4]. - The 30-day review and approval channel will support national key research varieties and encourage early global synchronized research and international multi-center clinical trials [3][4]. Categories of Supported Drugs - The drugs eligible for the expedited review include: 1. Nationally supported key innovative drugs with significant clinical value. 2. Drugs included in the NMPA's Children's Drug Star Program and Rare Disease Care Program. 3. Globally synchronized research varieties, including Phase I, II clinical trials, and international multi-center clinical trials led by Chinese principal investigators [3][4][5]. Impact on Clinical Trial Efficiency - The reduction of the approval timeline from the conventional 60 working days to 30 days (and even 18 days in some regions) is expected to significantly enhance the initiation efficiency of clinical trials, thereby accelerating the pace of research and reducing costs and risks for companies [4][5]. - For instance, a typical oncology drug could see its Phase III multi-center clinical trial approval time reduced by 55 days, potentially allowing for market entry six months earlier [4][5]. Encouragement for Global Collaboration - The inclusion of global synchronized research in the priority channel is anticipated to increase China's attractiveness as a key site for international multi-center clinical trials, motivating multinational pharmaceutical companies to incorporate China into their early global plans [5][8]. Regulatory and Operational Requirements - The draft emphasizes the responsibility of applicants to engage with clinical trial institutions before submitting applications, ensuring that they have the capacity for risk assessment and management [8][9]. - A commitment to initiate clinical trials within 12 weeks post-approval is mandated, which aims to prevent resource idling and compel companies to enhance their clinical operational capabilities [10][12]. Focus on Rare Diseases and Children's Drugs - The draft specifically addresses the needs of "niche" diseases, highlighting the importance of children's drugs and rare disease medications, which have historically faced a lack of systematic policy support in China [10][11]. - The inclusion of these drugs in the fast-track channel is seen as a critical incentive to address the insufficient research motivation in these areas [10][11]. Challenges and Considerations - While the draft presents opportunities, it also raises the bar for companies, requiring them to establish robust risk management and drug safety systems to align with the accelerated timelines [12]. - The implementation of this draft will necessitate careful attention to regional disparities in institutional capabilities and the prevention of local protectionism in the regulatory process [12].

Market Overview - The Hong Kong stock market continued its rebound with the Hang Seng Index rising by 0.6% to close at 23,654, while the Hang Seng Tech Index also increased by 0.6% to 5,219. The trading volume reached HKD 212.6 billion, indicating active trading, although net inflows from the Stock Connect decreased by about 10% to HKD 3.5 billion [1] - The market showed a "stronger gets stronger" trend, with funds continuing to favor high-certainty stocks. New consumption leaders like Pop Mart (9992 HK) and Mao Geping (1318 HK) reached new highs, reflecting market premium recognition for scarce consumer brands [1] Macro Dynamics - In the U.S., job vacancies rose to 7.391 million in April, an increase of 191,000 from March, indicating resilience in the labor market. The ratio of job openings to job seekers remained at 1.03, consistent with 2019 levels [2] - Despite a rise in layoffs to 1.79 million, the layoff rate remains relatively low, suggesting that companies are hesitant to reduce staff amid a moderately slowing economy [2] Industry Dynamics Automotive Sector - The Chinese government is promoting the "2025 New Energy Vehicles Going to the Countryside" initiative, with 124 models included in the directory, including vehicles from BYD and Geely. The automotive sector in Hong Kong showed stable performance, with most stocks fluctuating between -1% and +2% [3] Consumer Sector - The new consumption and IP concept sectors continue to attract capital. Companies like Blucor (325 HK) have entered the Mexican market, showcasing their product matrix at exhibitions. Blucor and Pop Mart saw respective increases of 17% and 14% over the past five trading days [3] Healthcare Sector - The Hang Seng Healthcare Index rose by 3.2%, driven by recent licensing agreements between domestic pharmaceutical companies and global firms, boosting confidence in the export of innovative drugs. Companies like Innovent Biologics (1801 HK) reported promising clinical data at the ASCO conference, leading to a 14.1% surge in their stock price [4] Energy Sector - The energy sector, particularly nuclear and renewable energy stocks, saw significant gains. China General Nuclear Power (1164 HK) rose by 28.3% after signing a uranium sales framework agreement, benefiting from rising uranium prices due to increased demand from U.S. nuclear energy initiatives [5][9] Company-Specific Insights Huaneng International (902 HK) - The company reported an 8.2% year-on-year increase in net profit for Q1 2025, benefiting from lower fuel costs and increased electricity demand during the summer [11] China General Nuclear Power (1164 HK) - The company is expected to benefit from a new uranium sales agreement, with a pricing mechanism favoring current market prices, enhancing its position amid rising uranium demand [11] Stone Pharmaceutical (1093 HK) - The company experienced a 21.9% decline in total revenue for Q1 2025, primarily due to a slowdown in its core product sales. However, it anticipates a gradual recovery in sales starting from Q2 2025, supported by new licensing agreements and increased sales of oncology drugs [13][14][15]

Core Viewpoint - 恒瑞医药 is a leading innovative pharmaceutical company in China, recently launched its IPO in Hong Kong, and is compared to other industry leaders like 宁德时代. The stock's pricing and foreign investment interest are under scrutiny, with a notable discount compared to its A-share price. Group 1: Company Overview - 恒瑞医药 has a market capitalization of 342.5 billion RMB and is recognized as a major player in the innovative drug sector [1] - The company has over 110 commercialized drugs, including 19 new molecular entity innovative drugs, and a pipeline of over 90 candidate new molecular entities [7] - In 2024, 52% of 恒瑞医药's revenue is expected to come from oncology drugs, with 15% from neuroscience [8] Group 2: Financial Performance - In 2024, 恒瑞医药's revenue is projected to reach 28 billion RMB, a year-on-year increase of 22.6%, with a net profit of 6.3 billion RMB, up 47% [9] - For Q1 2023, the company reported revenue of 7.2 billion RMB, a 20% increase year-on-year, and a net profit of 1.87 billion RMB, up 37% [11] - The revenue from innovative drugs increased from 38.1% in 2022 to 43.4% in 2023, and is expected to reach 46.3% in 2024 [13] Group 3: IPO Details - 恒瑞医药's IPO pricing range is set between 41.45 and 44.05 HKD, with a median price reflecting a 20.4% discount compared to its A-share price [3] - The subscription rate for the IPO is currently at 3.5 times, indicating moderate interest [5] - The company has engaged in 14 licensing transactions since 2018, generating approximately 14 billion USD in total transaction value, with 2.7 billion RMB expected from licensing in 2024 [15] Group 4: Market Position and Comparisons - Compared to 宁德时代, 恒瑞医药 has a lower foreign investment interest, with only 6% of its shares held by foreign investors as of Q1 2023 [1] - The discount on 恒瑞医药's IPO is higher than that of other innovative drug companies, such as 药明康德, which has a discount of only 4.2% [19] - The company’s P/E ratio is high at 50 times, and its P/S ratio is 11.7 times, indicating a premium valuation compared to peers [19]